Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$5.54 -8.7%	$6.09	$3.66 ▼ $8.40	$1.37B	0.58	4.10 million shs	17.50 million shs
BLTE Belite Bio	$148.73 -0.7%	$148.87	$56.10 ▼ $200.00	$5.96B	-1.24	235,838 shs	255,715 shs
COGT Cogent Biosciences	$38.12 +0.3%	$34.48	$7.07 ▼ $43.73	$6.51B	0.34	3.00 million shs	9.95 million shs
RGC Regencell Bioscience	$6.48 -13.5%	$23.14	$5.80 ▼ $69.00	$3.20B	1.66	199,553 shs	496,685 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	0.00%	-8.51%	-11.44%	+1.00%	+52.48%
BLTE Belite Bio	0.00%	+1.79%	+0.49%	-2.20%	+143.42%
COGT Cogent Biosciences	0.00%	+10.35%	+7.73%	+5.58%	+439.12%
RGC Regencell Bioscience	0.00%	-46.04%	-73.12%	-74.76%	-70.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$5.54 -8.7%	$6.09	$3.66 ▼ $8.40	$1.37B	0.58	4.10 million shs	17.50 million shs
BLTE Belite Bio	$148.73 -0.7%	$148.87	$56.10 ▼ $200.00	$5.96B	-1.24	235,838 shs	255,715 shs
COGT Cogent Biosciences	$38.12 +0.3%	$34.48	$7.07 ▼ $43.73	$6.51B	0.34	3.00 million shs	9.95 million shs
RGC Regencell Bioscience	$6.48 -13.5%	$23.14	$5.80 ▼ $69.00	$3.20B	1.66	199,553 shs	496,685 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	0.00%	-8.51%	-11.44%	+1.00%	+52.48%
BLTE Belite Bio	0.00%	+1.79%	+0.49%	-2.20%	+143.42%
COGT Cogent Biosciences	0.00%	+10.35%	+7.73%	+5.58%	+439.12%
RGC Regencell Bioscience	0.00%	-46.04%	-73.12%	-74.76%	-70.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.91	Moderate Buy	$15.73	184.14% Upside
BLTE Belite Bio	2.63	Moderate Buy	$203.00	36.49% Upside
COGT Cogent Biosciences	2.86	Moderate Buy	$43.73	14.72% Upside
RGC Regencell Bioscience	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARDX, RGC, COGT, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2026	RGC Regencell Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/16/2026	ARDX Ardelyx	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$16.00
6/15/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
5/29/2026	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$55.00
5/26/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$223.00 ➝ $215.00
5/22/2026	BLTE Belite Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$217.00
5/22/2026	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/21/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
5/6/2026	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00
4/22/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
4/20/2026	ARDX Ardelyx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$407.32M	3.36	N/A	N/A	$0.69 per share	8.02
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$3.84 per share	N/A
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$61.60M	-$0.23	N/A	9.88	N/A	-13.58%	-38.11%	-11.85%	8/3/2026 (Estimated)
BLTE Belite Bio	-$77.61M	-$2.53	N/A	122.92	N/A	N/A	-13.14%	-12.88%	8/10/2026 (Estimated)
COGT Cogent Biosciences	-$328.94M	-$2.17	N/A	N/A	N/A	N/A	-104.27%	-54.64%	8/4/2026 (Estimated)
RGC Regencell Bioscience	-$3.58M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ARDX, RGC, COGT, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2026	Q1 2026	BLTE Belite Bio	-$0.60	-$0.34	+$0.26	-$0.68	N/A	N/A
5/8/2026	Q1 2026	RGC Regencell Bioscience	N/A	-$0.0050	N/A	-$0.0050	N/A	N/A
5/5/2026	Q1 2026	COGT Cogent Biosciences	-$0.53	-$0.53	N/A	-$0.53	N/A	N/A
4/30/2026	Q1 2026	ARDX Ardelyx	-$0.13	-$0.15	-$0.02	-$0.15	$92.78 million	$94.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.37	3.49	3.28
BLTE Belite Bio	N/A	33.71	33.71
COGT Cogent Biosciences	0.41	15.14	15.14
RGC Regencell Bioscience	N/A	1.41	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
BLTE Belite Bio	0.53%
COGT Cogent Biosciences	N/A
RGC Regencell Bioscience	0.13%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.30%
BLTE Belite Bio	13.29%
COGT Cogent Biosciences	6.59%
RGC Regencell Bioscience	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	247.03 million	233.94 million	Optionable
BLTE Belite Bio	10	40.08 million	34.76 million	Not Optionable
COGT Cogent Biosciences	80	170.87 million	159.61 million	Optionable
RGC Regencell Bioscience	10	494.49 million	N/A	N/A

ARDX, RGC, COGT, and BLTE Headlines

Recent News About These Companies

Regencell Bioscience (NASDAQ:RGC) Hits New 1-Year Low - Here's What Happened

June 25 at 4:01 AM | americanbankingnews.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC

June 23, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 23, 2026 | prnewswire.com

Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

June 23, 2026 | businesswire.com

Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors

June 23, 2026 | globenewswire.com

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

June 23, 2026 | prnewswire.com

RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

June 23, 2026 | tmcnet.com

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

June 23, 2026 | prnewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | tmcnet.com

REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role

June 22, 2026 | globenewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC)Â Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | businesswire.com

DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

June 22, 2026 | globenewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC

June 22, 2026 | globenewswire.com

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited ...

June 21, 2026 | gazettextra.comG

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC

June 21, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 21, 2026 | globenewswire.com

RGC DEADLINE: The Gross Law Firm Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action Deadline

June 19, 2026 | globenewswire.com

Relevant Gold Announces Results of Annual and Special General Meeting and Welcomes New Board Member

June 18, 2026 | accessnewswire.comA

REGENCELL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC

June 18, 2026 | globenewswire.com

SueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC

June 18, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX, RGC, COGT, and BLTE Company Descriptions

Ardelyx NASDAQ:ARDX

$5.54 -0.53 (-8.66%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$5.62 +0.09 (+1.59%)

As of 06/26/2026 07:59 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Belite Bio NASDAQ:BLTE

$148.73 -1.10 (-0.73%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$148.36 -0.36 (-0.25%)

As of 06/26/2026 06:07 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Cogent Biosciences NASDAQ:COGT

$38.12 +0.11 (+0.28%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$38.20 +0.08 (+0.21%)

As of 06/26/2026 07:59 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Regencell Bioscience NASDAQ:RGC

$6.48 -1.01 (-13.48%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$6.38 -0.10 (-1.48%)

As of 06/26/2026 07:56 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARDX, RGC, COGT, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARDX, RGC, COGT, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARDX, RGC, COGT, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX, RGC, COGT, and BLTE Company Descriptions

Ardelyx NASDAQ:ARDX

Belite Bio NASDAQ:BLTE

Cogent Biosciences NASDAQ:COGT

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARDX, RGC, COGT, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARDX, RGC, COGT, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARDX, RGC, COGT, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX, RGC, COGT, and BLTE Company Descriptions

Ardelyx NASDAQ:ARDX

Belite Bio NASDAQ:BLTE

Cogent Biosciences NASDAQ:COGT

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools